Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STA-5326 mesylate for induction of clinical response in Crohn's disease
2005-002857-29Phase 2Terminated
- Sponsor
- Synta Pharmaceuticals Corp.
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing STA-5326 mesylate with Placebo (2 arms). Primary endpoints: Clinical remission at Day 29 and Clinical response at Day 29. Started Aug 2005; status: terminated.
02
Drugs
apilimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2005-002857-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002857-29.